Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

PR Newswire October 11, 2017

Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results

PR Newswire August 9, 2017

Investor Network: Ardelyx, Inc. to Host Earnings Call

Accesswire August 9, 2017

Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

PR Newswire August 2, 2017

Biotech Stock Performance Review -- Alder Biopharma, Ardelyx, Bellerophon Therapeutics, and Corbus Pharma

PR Newswire June 26, 2017

Mid-Afternoon Market Update: Inpixon Drops Following Q1 Results; Technical Communications Shares Spike Higher

Benzinga.com  May 12, 2017

18 Biggest Mid-Day Losers For Friday

Benzinga.com  May 12, 2017

Mid-Day Market Update: Trade Desk Rises After Q1 Results; Capricor Therapeutics Shares Slide

Benzinga.com  May 12, 2017

Mid-Morning Market Update: Markets Open Lower; J C Penney Reports Weak Sales

Benzinga.com  May 12, 2017

Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C

PR Newswire May 12, 2017

Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress

PR Newswire May 5, 2017

Adaptimmune Broadens Executive Team

GlobeNewswire March 15, 2017

Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference

PR Newswire February 27, 2017

Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results

PR Newswire February 17, 2017

Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease

PR Newswire February 15, 2017

Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia

PR Newswire January 3, 2017

Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference

PR Newswire January 3, 2017

Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress

PR Newswire November 7, 2016

Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016

PR Newswire October 31, 2016

Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer

PR Newswire October 24, 2016